Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
MNTA's Cash to Debt is ranked higher than
98% of the 1173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. MNTA: No Debt )
MNTA' s 10-Year Cash to Debt Range
Min: 10.74   Max: No Debt
Current: No Debt

Equity to Asset 0.83
MNTA's Equity to Asset is ranked higher than
90% of the 983 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. MNTA: 0.83 )
MNTA' s 10-Year Equity to Asset Range
Min: -0.49   Max: 0.96
Current: 0.83

-0.49
0.96
Interest Coverage No Debt
MNTA's Interest Coverage is ranked higher than
94% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 133.58 vs. MNTA: No Debt )
MNTA' s 10-Year Interest Coverage Range
Min: 110.84   Max: 9999.99
Current: No Debt

110.84
9999.99
F-Score: 3
Z-Score: 14.49
M-Score: -3.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -187.60
MNTA's Operating margin (%) is ranked lower than
53% of the 1117 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. MNTA: -187.60 )
MNTA' s 10-Year Operating margin (%) Range
Min: -548.56   Max: 63.48
Current: -187.6

-548.56
63.48
Net-margin (%) -186.13
MNTA's Net-margin (%) is ranked lower than
53% of the 1117 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.55 vs. MNTA: -186.13 )
MNTA' s 10-Year Net-margin (%) Range
Min: -546.42   Max: 63.71
Current: -186.13

-546.42
63.71
ROE (%) -42.46
MNTA's ROE (%) is ranked higher than
50% of the 1157 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.46 vs. MNTA: -42.46 )
MNTA' s 10-Year ROE (%) Range
Min: -66.11   Max: 59.21
Current: -42.46

-66.11
59.21
ROA (%) -35.38
MNTA's ROA (%) is ranked lower than
51% of the 1183 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.53 vs. MNTA: -35.38 )
MNTA' s 10-Year ROA (%) Range
Min: -389.52   Max: 55.62
Current: -35.38

-389.52
55.62
ROC (Joel Greenblatt) (%) -374.33
MNTA's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 1178 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.83 vs. MNTA: -374.33 )
MNTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1125.81   Max: 348.38
Current: -374.33

-1125.81
348.38
Revenue Growth (3Y)(%) -43.40
MNTA's Revenue Growth (3Y)(%) is ranked lower than
52% of the 971 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. MNTA: -43.40 )
MNTA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 138.6
Current: -43.4

0
138.6
» MNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MNTA Guru Trades in Q2 2014

Jim Simons 540,251 sh (+27.08%)
PRIMECAP Management 2,670,600 sh (+23.67%)
Steven Cohen 478,500 sh (unchged)
Paul Tudor Jones Sold Out
John Burbank Sold Out
Steven Cohen 2,395,088 sh (-18.58%)
» More
Q3 2014

MNTA Guru Trades in Q3 2014

Steven Cohen 554,400 sh (+15.86%)
PRIMECAP Management 2,670,600 sh (unchged)
Jim Simons 366,351 sh (-32.19%)
» More
Q4 2014

MNTA Guru Trades in Q4 2014

Chuck Royce 2,000 sh (New)
PRIMECAP Management 2,670,600 sh (unchged)
Jim Simons 230,351 sh (-37.12%)
Steven Cohen 302,800 sh (-45.38%)
» More
Q1 2015

MNTA Guru Trades in Q1 2015

Joel Greenblatt 14,216 sh (New)
Jim Simons 234,451 sh (+1.78%)
PRIMECAP Management 2,695,100 sh (+0.92%)
PRIMECAP Management 2,695,100 sh (+0.92%)
Chuck Royce Sold Out
Steven Cohen 254,900 sh (-15.82%)
» More
» Details

Insider Trades

Latest Guru Trades with MNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 38.17
MNTA's Forward P/E is ranked higher than
73% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MNTA: 38.17 )
N/A
P/B 4.90
MNTA's P/B is ranked higher than
57% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. MNTA: 4.90 )
MNTA' s 10-Year P/B Range
Min: 1.34   Max: 14.92
Current: 4.9

1.34
14.92
P/S 20.24
MNTA's P/S is ranked lower than
69% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. MNTA: 20.24 )
MNTA' s 10-Year P/S Range
Min: 1.84   Max: 60.6
Current: 20.24

1.84
60.6
EV-to-EBIT -10.67
MNTA's EV-to-EBIT is ranked lower than
55% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.19 vs. MNTA: -10.67 )
MNTA' s 10-Year EV-to-EBIT Range
Min: -52.2   Max: 17.4
Current: -10.67

-52.2
17.4
Current Ratio 9.12
MNTA's Current Ratio is ranked higher than
93% of the 1051 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. MNTA: 9.12 )
MNTA' s 10-Year Current Ratio Range
Min: 4.39   Max: 28.87
Current: 9.12

4.39
28.87
Quick Ratio 9.12
MNTA's Quick Ratio is ranked higher than
94% of the 1051 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. MNTA: 9.12 )
MNTA' s 10-Year Quick Ratio Range
Min: 4.39   Max: 28.87
Current: 9.12

4.39
28.87
Days Sales Outstanding 42.84
MNTA's Days Sales Outstanding is ranked higher than
89% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 91.38 vs. MNTA: 42.84 )
MNTA' s 10-Year Days Sales Outstanding Range
Min: 36.32   Max: 506.58
Current: 42.84

36.32
506.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.10
MNTA's Price/Net Cash is ranked higher than
92% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MNTA: 7.10 )
MNTA' s 10-Year Price/Net Cash Range
Min: 2.03   Max: 14.33
Current: 7.1

2.03
14.33
Price/Net Current Asset Value 6.90
MNTA's Price/Net Current Asset Value is ranked higher than
90% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MNTA: 6.90 )
MNTA' s 10-Year Price/Net Current Asset Value Range
Min: 1.55   Max: 11.36
Current: 6.9

1.55
11.36
Price/Tangible Book 5.20
MNTA's Price/Tangible Book is ranked higher than
68% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. MNTA: 5.20 )
MNTA' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 10.14
Current: 5.2

1.5
10.14
Price/DCF (Projected) 10.60
MNTA's Price/DCF (Projected) is ranked higher than
69% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MNTA: 10.60 )
MNTA' s 10-Year Price/DCF (Projected) Range
Min: 1.77   Max: 8.31
Current: 10.6

1.77
8.31
Price/Median PS Value 1.00
MNTA's Price/Median PS Value is ranked higher than
90% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. MNTA: 1.00 )
MNTA' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 2.86
Current: 1

0.1
2.86
Earnings Yield (Greenblatt) -10.00
MNTA's Earnings Yield (Greenblatt) is ranked lower than
56% of the 1170 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. MNTA: -10.00 )
MNTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10   Max: 78
Current: -10

-10
78

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LZ1.Germany,
Momenta Pharmaceuticals Inc was incorporated in the state of Delaware in May 2001 under the name of Mimeon, Inc., later changed the name Momenta Pharmaceuticals, Inc. in September 2002. The Company is a biotechnology company operating in three product areas: Complex Generics, Biosimilars and Novel Drugs. In Complex Generics product area, the Company develops generic versions of complex drugs that were approved by the United States Food and Drug Administration under New Drug Applications. Enoxaparin Sodium Injection is the Company's first product to receive marketing approval under ANDA. The second complex generic product candidate, M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a complex drug consisting of a synthetic mixture of polypeptide chains. In Biosimilars product area, the Company is seeking to develop biosimilar versions of biologic medicines that were approved by the FDA under Biologics License Applications. Biologics are complex mixtures, and the Company unlocks their structural subtleties using an approach that is similar to the one it uses in the development of complex generics. Novel Drugs program uses the established characterization and process engineering capabilities from complex generics and biosimilars programs with a focus on polysaccharides and therapeutic proteins. Momenta were originally founded to develop novel drugs and it remains the long term goal for the Company. As with the complex generics and biosimilars the Company's platform gives a detailed understanding of the complex structures of novel product candidates, their associated manufacturing processes and controls, and the targeted biologic systems. The Company license or own a patent portfolio of over 95 patent families, each of which includes United States patent applications and/or issued patents as well as foreign counterparts. The Company relies on contract manufacturers since it does not own facilities for manufacturing any products.
» More Articles for MNTA

Headlines

Articles On GuruFocus.com
Very Low P/E Stocks Joel Greenblatt selected Dec 22 2011 
Momenta Pharmaceuticals Inc. (MNTA) SVP, CFO Richard P Shea sells 979 Shares Feb 24 2011 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 45,296 Shares Aug 05 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 7,800 Shares Mar 12 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 32,200 Shares Mar 10 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 1,413 Shares Mar 03 2010 

More From Other Websites
MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 20 2015
1:21 am Momenta Pharma prices 7,250,000 shares of common stock at $19.00 per share May 20 2015
Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock May 19 2015
Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock May 19 2015
Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock May 18 2015
Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock May 18 2015
Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual... May 18 2015
Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual... May 18 2015
Momenta Pharmaceuticals to Webcast Presentation at the UBS 2015 Global Healthcare Conference May 12 2015
Momenta Pharmaceuticals to Webcast Presentation at the UBS 2015 Global Healthcare Conference May 12 2015
Surging Earnings Estimates Signal Good News for Momenta Pharmaceuticals (MNTA) - Tale of the Tape May 12 2015
10-Q for Momenta Pharmaceuticals, Inc. May 07 2015
Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch 2015 Health... May 06 2015
Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch 2015 Health... May 06 2015
Aegerion's Q1 Loss Narrower than Expected, View Retained - Analyst Blog May 05 2015
MOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 05 2015
Momenta's Q1 Loss Narrower than Expected, Revenues Miss - Analyst Blog May 04 2015
Here's why Momenta's generic MS drug may not bring down costs much May 04 2015
Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 40th Annual Health Care... May 01 2015
Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 40th Annual Health Care... May 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK